Inebilizumab

Definition

A humanized immunoglobulin IgG1 kappa monoclonal antibody directed against the B-cell-specific membrane protein CD-19 with potential immunostimulating and antineoplastic activities. Inebilizumab binds to CD19, which may result in a cytotoxic T-lymphocyte (CTL) response and antibody-dependent cellular cytotoxicity (ADCC) to CD19-expressing B-cells. The Fc portion of inebilizumab does not contain a fucose sugar moiety, which may contribute to its enhanced ADCC activity. CD19 is a membrane antigen that is widely expressed during B-cell development, from pro-B-cell to early plasma cell stages.

Also known as INEBILIZUMAB, MEDI-551 — per NCIT

Also identified as

• ATC L04AG10 per RXNORM
• NCIT NCIT:C88283 per NCIT
• SCTID 879883007 per RXNORM
• SCTID 879892005 per RXNORM
• UNII 74T7185BMM per RXNORM

Indications